Dr. Javed's research focuses on on Nano-pharmaceuticals and biological interfaces

Dr. Javed's research focuses on the synthesis of pharmaceutically functional nano-materials and their interfacial interactions with amyloid proteins like human Islet Amyloid Polypeptide, Amyloid-beta and alpha-Synuclein that are involved in the pathogenesis of type-2-diabetes, Alzheimer's and Parkinson's diseases. He has developed in vivo model systems, using zebrafish, to study the pathogenesis of amyloid diseases as well as interaction, fate and mitigation profiling of nanomaterials against amyloid diseases. Dr. Javed's is also working on biofilm component of bacterial biofilm (like FapC from Pseudomonas and CsgA from E. coli) and Gut-Brain axis to unravel the associations of gut microbiome with the development of amyloid based neurological disorders.

​​Dr. Ibrahim Javed is Postdoctoral Research Fellow at ARC Centre of Excellence in Convergent Nano-Bio Science and Technology and Australian Institute for Bioengineering and Nanotechnology at The University of Queensland. He earned his PhD degree from Monash Institute of Pharmaceutical Sciences at Monash University in 2019. Prior to PhD, Dr. Javed had graduated with Doctor of Pharmacy degree in 2011 from University of Sargodha and Master of Philosophy in Pharmaceutical Chemistry in 2014 from Bahauddin Zakariya University, Pakistan. Later on he worked as Research Assistant (2013-16) at Department of Chemistry, Lahore University of Management Sciences where he developed nano-pharmaceuticals for drug delivery and to improve the pharmacokinetic profiles of hydrophobic drugs. With extensive research experience in the synthesis of pharmaceutical nanomaterials, in vivo modelling, pharmacokinetics and protein misfolding and aggregation, Dr. Javed has published >50 research publications in prestigious journals like Nature Communications, Nano Letter, Small,  Chemistry of Materials, ACS Applied Materials & Interfaces, Nanoscale, Biomacromolecules and Materials Chemistry B.


Dr. Javed is working with a number of national and international collaborations including Prof. Pu Chun Ke at Monash University & Fudan University, Prof. Clare Parish at The Florey Institute, Prof. Sijie Lin at Tongji University, A/Prof. Feng Ding from Clemson University, Prof. Raffaele Mezzenga at ETH and Prof. Daniel Otzen from Aarhus University. 

Key Publications

Javed, I., Peng, G., Xing, Y., Yu, T., Zhao, M., Kakinen, A., Faridi, A., Parish, C.L., Ding, F., Davis, T.P., Ke, P.C. and Lin, S., 2019. Inhibition of amyloid beta toxicity in zebrafish with a chaperone-gold nanoparticle dual strategy. Nature communications, 10(1), pp.1-14.

Javed, I., Yu, T., Peng, G., Sánchez-Ferrer, A., Faridi, A., Kakinen, A., Zhao, M., Mezzenga, R., Davis, T.P., Lin, S. and Ke, P.C., 2018. In vivo mitigation of amyloidogenesis through functional–pathogenic double-protein coronae. Nano letters, 18(9), pp.5797-5804.

Kakinen, A., Xing, Y., Hegoda Arachchi, N., Javed, I., Feng, L., Faridi, A., Douek, A.M., Sun, Y., Kaslin, J., Davis, T.P., Higgins, M.J., Ding, F. and Ke, P.C., 2019. Single-Molecular Heteroamyloidosis of Human Islet Amyloid Polypeptide. Nano letters, 19(9), pp.6535-6546.

Ke, P.C., Pilkington, E.H., Sun, Y., Javed, I., Kakinen, A., Peng, G., Ding, F. and Davis, T.P., 2019. Mitigation of amyloidosis with nanomaterials. Advanced Materials, p.1901690.

Ke, P.C., Sani, M.A., Ding, F., Kakinen, A., Javed, I., Separovic, F., Davis, T.P. and Mezzenga, R., 2017. Implications of peptide assemblies in amyloid diseases. Chemical Society Reviews, 46(21), pp.6492-6531.